LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
LIGAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$297.28+1.74 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $6.49B
- P/E (TTM)
- 31.6
- Dividend yield
- –
Ligand Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $5.93B | $164.85M |
| Enterprise Value | $4.57B | $87.06M |
| PE Ratio | 31.63 | 19.63 |
| PS Ratio | 20.40 | 3.60 |
| PB Ratio | 6.13 | 2.03 |
| P/TBV Ratio | 9.02 | 2.31 |
| P/FCF Ratio | 45.09 | 17.44 |
| P/OCF Ratio | 44.99 | 13.32 |
Enterprise value
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 15.72 | 2.43 |
| EV / EBITDA | 35.79 | 14.69 |
| EV / EBIT | 48.23 | 18.47 |
| EV / FCF | 34.76 | 20.97 |
Income (trailing twelve months)
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $290.54M | $57.94M |
| Operating Income | $94.73M | -$21.44M |
| Pretax Income | $237.96M | -$14.45M |
| Net Income | $197.22M | -$22.46M |
| EBITDA | $127.65M | -$16.91M |
| EPS (Diluted) | $9.40 | -$0.83 |
Margins
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | 32.6% | -44.5% |
| Pretax Margin | 81.9% | -13.0% |
| Profit Margin | 67.9% | -39.2% |
| EBITDA Margin | 43.9% | -31.3% |
| FCF Margin | 45.2% | -8.85% |
Returns
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 22.0% | -53.1% |
| Return on Assets (ROA) | 12.6% | -41.0% |
| Return on Invested Capital (ROIC) | 81.8% | -32.0% |
| Return on Capital Employed (ROCE) | 4.43% | -37.8% |
Growth
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 54.9% | 6.01% |
| FCF Growth (YoY) | 145.1% | 2.34% |
| Revenue Growth (3Y CAGR) | 11.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 10.4% | 6.42% |
Balance sheet
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.36B | $62.42M |
| Net Cash (Debt) | $1.36B | $15.68M |
| Net Cash Per Share | $68.11 | $0.66 |
| Equity (Book Value) | $967.52M | $48.79M |
| Book Value Per Share | $48.53 | $1.36 |
| Tangible Book Value | $656.73M | $23.06M |
| Working Capital | $1.41B | $75.77M |
Financial position
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 31.18 | 3.30 |
| Quick Ratio | 30.49 | 2.39 |
| Interest Coverage | 15.30 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $131.71M | -$12.35M |
| Capital Expenditures | -$278.00K | -$1.06M |
| Free Cash Flow | $131.44M | -$20.28M |
| FCF Per Share | $6.59 | -$0.42 |
Efficiency
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.19 | 0.38 |
| Revenue Per Employee | $6.18M | $398.96K |
| Profits Per Employee | $4.20M | -$703.34K |
| Employee Count | 47 | 74 |
Dividends and yields
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 3.33% | -22.7% |
| FCF Yield | 2.22% | -9.07% |
Shares
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 19,935,600 | 58,179,650 |
| Shares Change (YoY) | 10.7% | 11.1% |
| Shares Change (QoQ) | -0.54% | 0.54% |
| Float | 19,411,200 | 49,173,100 |
| Shares Held by Insiders | 2.63% | 11.6% |
| Shares Held by Institutions | 113.7% | 59.4% |
Taxes
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $40.74M | $91.50K |
| Effective Tax Rate | 17.1% | 20.6% |
Scores
| Measure | Ligand Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $101.31 | $17.36 |
| Graham Upside | -65.9% | -43.6% |
| Altman Z-Score | 4.34 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Ligand Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.